Multiple sclerosis in 2016: Immune-directed therapies in MS — efficacy and limitations
Nat Rev Neurol. 2017 Feb;13(2):72-74. doi: 10.1038/nrneurol.2017.2. Epub 2017 Jan 20.
|Authors/Editors:||Hemmer B, Mühlau M.|
In 2016, new highly active treatment options for relapsing–remitting multiple sclerosis (MS) emerged. At the same time, large clinical trials in progressive MS highlighted the limitations of immune-directed therapies, and called for new strategies to treat disease progression in MS.
During the past two decades, several immune therapies have been established for clinically isolated syndrome (CIS) and relapsing–remitting multiple sclerosis (RRMS). For all the drugs that have been approved to date, efficacy and safety inversely correlate. However, work reported in 2016 has demonstrated that B‑cell depletion with CD20‑specific monoclonal antibodies (such as rituximab, ocrelizumab and ofatumumab) is a safe and effective treatment strategy for RRMS.